Table 2.
Effect of treatment on the values of clinical measures in follow-up AIH patients.
| Parameters | Before treatment | After treatment |
|---|---|---|
| Number | 19 | 19 |
| Age (years) | 42 (37–76) | 42 (37–76) |
| Gender: female/male | 16/3 | 16/3 |
| ALT (U/L) | 184.6 ± 105.3∗ | 37.2 ± 10.4 |
| AST (U/L) | 126.4 ± 54.8∗ | 43.6 ± 11.5 |
| γ-GT (U/L) | 105.6 ± 26.1∗ | 76.1 ± 24.9 |
| ALP (U/L) | 152.5 ± 33.3∗ | 93.7 ± 23.2 |
| IgG (g/L) | 17.7 ± 3.1∗ | 8.7 ± 2.9 |
| IgM (g/L) | 7.8 ± 1.6∗ | 4.5 ± 2.3 |
| IgA (g/L) | 3.9 ± 1.7∗ | 2.6 ± 1.1 |
Data shown are the real case number or mean ± SD. Normal values: ALT: <40 IU/L; AST: <40 IU/L. IgG (normal range: 7–16 g/L); IgM (normal range: 0.7–4.6 g/L); IgA (normal range: 0.4–2.3 g/L). HC: healthy control; AIH: autoimmune hepatitis. ∗p < 0.05 versus posttreatment.